Back to targets

Target detail

ACSL3

acyl-CoA synthetase long chain family member 3

Data: Live structured evidence (Supabase)

Marker index metadata

Foundation row from public.targets — full Open Targets / ChEMBL preload remains a future operator job (Phase 8H+).

Display name: acyl-CoA synthetase long chain family member 3

Aliases: ACSL3, acyl-CoA synthetase long chain family member 3

Type / organism: protein_coding · Homo sapiens

Source: opentargets · ENSG00000123983

Index freshness: last_synced_at 2026-05-15T19:30:17.094+00:00 · updated 2026-05-15T19:30:17.638733+00:00

Limitations & build flags

  • Read-only structured navigator
  • No clinical outcome benefit inferred
  • Trial presence does not imply success
  • Drug identity may require normalization
  • Terminated/withdrawn trials must remain visible
Target index (foundation)

This symbol is listed in public.targets (operator seed or future preload). Connector-backed sections below may still show empty states until ChEMBL / Open Targets / ClinicalTrials.gov mirror rows exist for this marker.

Live structured evidence · sources

Connectors represented in loaded rows for ACSL3. Empty groups mean no matching rows — not a claim about biology or clinical use.

  • Open TargetsLive when indexed

    Disease–target evidence rows when operators run enrich:opentargets (GraphQL from trusted scripts only).

  • ChEMBLLive when indexed

    Drug–target and related enrichment rows when operators run enrich:chembl (server/CLI only).

Open Targets · disease–target evidence

Rows from disease_target_evidence for this symbol.

glioblastoma

literature · opentargets

ChEMBL · linked drugs (drug_targets)

Drug records tied via drug_targets — mechanistic linkage only.

CHEMBL5653589

chembl5653589

Open drug

CHEMBL4761388

chembl4761388

Open drug

CHEMBL4798042

chembl4798042

Open drug

CHEMBL3752910

chembl3752910

Open drug

CHEMBL4749993

chembl4749993

Open drug

CHEMBL4778736

chembl4778736

Open drug

CHEMBL222502

chembl222502

Open drug

CHEMBL4776019

chembl4776019

Open drug

CHEMBL4792940

chembl4792940

Open drug

CHEMBL4789782

chembl4789782

Open drug

CHEMBL4757253

chembl4757253

Open drug

CHEMBL4751846

chembl4751846

Open drug
repoDB-style · approved-elsewhere discussion candidates

disease_drug_evidence rows on linked drugs whose evidence_type suggests approved-elsewhere discussion context.

No matching rows

Import repoDB-compatible disease–drug evidence or add structured rows to surface discussion candidates here.

ClinicalTrials.gov · trial-matched options

Mirror rows whose text fields mention this symbol — registry context only.

No matching live evidence found

Populate clinical_trials via the registry enrichment flow; this panel matches the symbol token in titles, conditions, or interventions.

CANTI signal builder · target-linked research signals

Repurposing signal rows for drugs linked to this target via drug_targets.

No research signals for linked drugs

Run the deterministic signal builder after drug_targets and source rows are present.

Caution / negative-evidence rows

Structured rows with negative evidence_direction on disease–drug or signal tables.

No negative-direction rows

When structured evidence includes explicit negative direction fields, they surface here for oncology review.

Missing evidence · row counts by source string

No ClinicalTrials.gov mirror rows mention this symbol in titles, conditions, or interventions (within the loaded window).

  • chembl: 12
  • opentargets: 1
Summary row (aggregated list)

Structured evidence rows link this marker to cohort contexts when ingested — interpret as research context only.

Disease contexts

0

Linked drugs

0

Linked in dataset

0

Research signals

0

Evidence badges (illustrative)

Doctor-discussion candidate and related tags are descriptive only.

Appears in source landscapeLinked in datasetRequires oncology review
Linked research signals (list read)

Signals list: Live structured evidence (Supabase)

No matching live evidence found

When repurposing_signal rows reference this marker via linked drugs, summaries appear here.